LPL Financial LLC Raises Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

LPL Financial LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,960 shares of the company's stock after acquiring an additional 909 shares during the quarter. LPL Financial LLC owned about 0.06% of Medpace worth $6,010,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. State Street Corp lifted its holdings in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after acquiring an additional 50,312 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Medpace by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock valued at $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. GW&K Investment Management LLC increased its position in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after purchasing an additional 133,379 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after buying an additional 241,827 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Up 5.5 %

Medpace stock traded up $15.39 during trading on Friday, reaching $297.72. The stock had a trading volume of 660,021 shares, compared to its average volume of 318,810. Medpace Holdings, Inc. has a 52-week low of $272.00 and a 52-week high of $459.77. The stock has a market cap of $9.00 billion, a PE ratio of 23.57, a P/E/G ratio of 3.81 and a beta of 1.46. The business has a 50 day moving average price of $323.58 and a 200 day moving average price of $334.41.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent analyst reports. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Mizuho lowered their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Finally, Truist Financial lowered their target price on Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a report on Thursday. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $361.90.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.